Theseus Pharmaceuticals is engaged in the discovery, development and commercialization of targeted therapies for cancer patients. Co.'s development programs are designed to address drug resistance mutations in key driver oncogenes. Co.'s product candidate, THE-630, is a pan-variant inhibitor of all main classes of activating and resistance mutations of the KIT kinase for the treatment of gastrointestinal stromal tumours. Co.'s second program is focused on inhibitors of epidermal growth factor receptor (EGFR), that are active against C797S, the common EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. When considering the Theseus Pharmaceuticals Inc stock dividend history, we have taken known splits into account, such that the THRX dividend history is presented on a split-adjusted ("apples to apples") basis. Theseus Pharmaceuticals Inc dividend history is presented both in graphical/chart form, and as a THRX dividend history data table along the right-hand column.
|
THRX Stock Dividend HistoryThe THRX dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable THRX historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the THRX dividend history record. Also see the THRX stock dividend history data table along the right-hand column below. |
|
THRX Next Dividend Date » (Projection based upon history) Quotes delayed 20 minutes |
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
Projection: THRX Next Dividend Date Chart: THRX Chart - 5Yr Dividend Yield |